For the quarter ended September 2024, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.05 billion, up 8.5% over the same period last year. EPS came in at $6.61, compared to $4.84 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.04 billion, representing a surprise of +1.75%. The company delivered an EPS surprise of +20.84%, with the consensus EPS estimate being $5.47.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...